Application of single-layer continuous duct-to-mucosa pancreaticojejunostomy in oncologic pancreaticoduodenectomy

IF 2.5 3区医学 Q2 ONCOLOGY

Seminars in oncology Pub Date : 2025-09-11 DOI:10.1016/j.seminoncol.2025.152415

Qun Chen , Fengyuan Liu , Lingtao Yan , Xumin Huang , Jishu Wei , Feng Guo , Jianmin Chen , Zipeng Lu , Junli Wu , Jie Yin , Pengfei Wu , Kuirong Jiang

{"title":"Application of single-layer continuous duct-to-mucosa pancreaticojejunostomy in oncologic pancreaticoduodenectomy","authors":"Qun Chen , Fengyuan Liu , Lingtao Yan , Xumin Huang , Jishu Wei , Feng Guo , Jianmin Chen , Zipeng Lu , Junli Wu , Jie Yin , Pengfei Wu , Kuirong Jiang","doi":"10.1016/j.seminoncol.2025.152415","DOIUrl":null,"url":null,"abstract":"<div><div>Pancreaticojejunostomy is a critical step in pancreaticoduodenectomy, and its failure often results in pancreatic fistula. Clinically relevant pancreatic fistula (CRPF) can cause severe complications. This study evaluates the safety and feasibility of single-layer continuous duct-to-mucosa (SCD) pancreaticojejunostomy in preventing CRPF. We prospectively collected baseline characteristics and perioperative data from patients who underwent SCD pancreaticojejunostomy at our center between January and December 2020. A total of 156 patients were included in this study. The mean pancreaticojejunostomy time was 6.5 min, and the mean operation time was 247.6 min. CRPF occurred in 31 patients (19.9%), severe complications (Clavien-Dindo classification ≥III) occurred in 27 patients (17.3%), the mean length of hospitalization was 17.2 days, and the 90-days mortality was 0.0%. SCD pancreaticojejunostomy is an efficient and straightforward technique. It is applicable to various pancreatic conditions and demonstrates favorable clinical outcomes.</div></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"52 6","pages":"Article 152415"},"PeriodicalIF":2.5000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0093775425001071","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreaticojejunostomy is a critical step in pancreaticoduodenectomy, and its failure often results in pancreatic fistula. Clinically relevant pancreatic fistula (CRPF) can cause severe complications. This study evaluates the safety and feasibility of single-layer continuous duct-to-mucosa (SCD) pancreaticojejunostomy in preventing CRPF. We prospectively collected baseline characteristics and perioperative data from patients who underwent SCD pancreaticojejunostomy at our center between January and December 2020. A total of 156 patients were included in this study. The mean pancreaticojejunostomy time was 6.5 min, and the mean operation time was 247.6 min. CRPF occurred in 31 patients (19.9%), severe complications (Clavien-Dindo classification ≥III) occurred in 27 patients (17.3%), the mean length of hospitalization was 17.2 days, and the 90-days mortality was 0.0%. SCD pancreaticojejunostomy is an efficient and straightforward technique. It is applicable to various pancreatic conditions and demonstrates favorable clinical outcomes.

查看原文本刊更多论文

单层连续胰-黏膜胰空肠吻合术在肿瘤胰十二指肠切除术中的应用

胰空肠吻合术是胰十二指肠切除术的关键步骤，其失败常导致胰瘘。临床相关胰瘘（CRPF）可引起严重的并发症。本研究评价单层连续胰空肠管粘膜吻合术预防CRPF的安全性和可行性。我们前瞻性地收集了2020年1月至12月在我们中心接受SCD胰空肠吻合术的患者的基线特征和围手术期数据。本研究共纳入156例患者。平均胰空肠吻合时间为6.5 min，平均手术时间为247.6 min。发生CRPF 31例（19.9%），严重并发症（Clavien-Dindo分级≥III） 27例（17.3%），平均住院时间17.2天，90天死亡率0.0%。SCD胰空肠吻合术是一种简单有效的技术。它适用于各种胰腺疾病，并具有良好的临床效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in oncology 医学-肿瘤学

CiteScore

6.60

自引率

0.00%

发文量

审稿时长

104 days

期刊介绍： Seminars in Oncology brings you current, authoritative, and practical reviews of developments in the etiology, diagnosis and management of cancer. Each issue examines topics of clinical importance, with an emphasis on providing both the basic knowledge needed to better understand a topic as well as evidence-based opinions from leaders in the field. Seminars in Oncology also seeks to be a venue for sharing a diversity of opinions including those that might be considered "outside the box". We welcome a healthy and respectful exchange of opinions and urge you to approach us with your insights as well as suggestions of topics that you deem worthy of coverage. By helping the reader understand the basic biology and the therapy of cancer as they learn the nuances from experts, all in a journal that encourages the exchange of ideas we aim to help move the treatment of cancer forward.